Last --
Change Today 0.00 / 0.00%
Volume 0.0
500672 On Other Exchanges
Symbol
Exchange
500672 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

novartis india ltd (500672) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
$-0.41
Shares Outstanding
7.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVARTIS INDIA LTD (500672)

Related News

No related news articles were found.

novartis india ltd (500672) Related Businessweek News

No Related Businessweek News Found

novartis india ltd (500672) Details

Novartis India Limited manufactures and sells healthcare products in India and internationally. It operates through four segments: Pharmaceuticals, Generics, Over-The-Counter, and Animal Health. The Pharmaceuticals segment offers a portfolio of prescription medicines through healthcare professionals. The Generics segment offers retail generics products in various therapeutic areas, such as anti-TB, anti-DUB (gynecology), anti-histamines, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. The Over-The-Counter segment offers vitamins, minerals, and nutritional supplements, as well as products for the treatment of cough, cold, and allergy. The Animal Health segment offers products for the cattle and poultry markets. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG.

Founded in 1947

novartis india ltd (500672) Top Compensated Officers

Managing Director, Vice Chairman, Chairman of...
Total Annual Compensation: 17.0M
Chief Financial Officer
Total Annual Compensation: 7.5M
Compliance Officer and Company Secretary
Total Annual Compensation: 4.7M
Executive Officer
Total Annual Compensation: --
Executive Officer of OTC
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

novartis india ltd (500672) Key Developments

Novartis India Limited Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Full Year Ended of March 31, 2016

Novartis India Limited reported unaudited standalone earnings results for the fourth quarter and full year ended of March 31, 2016. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 153.61 million compared to INR 202.38 million a year ago. Profit from operations before other income and finance costs was INR 9.62 million compared to INR 16.14 million a year ago. Profit from ordinary activities before tax was INR 30.59 million compared to INR 52.91 million a year ago. Net profit for the period was INR 21.53 million compared to INR 51.94 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 6.73 compared to INR 16.25 a year ago. For the full year, the company reported net sales/income from operations (net of excise duty) of INR 768.42 million compared to INR 845.29 million a year ago. Profit from operations before other income and finance costs was INR 19.75 million compared to loss from operations before other income and finance costs of INR 7.87 million a year ago. Profit from ordinary activities before tax was INR 102.51 million compared to INR 99.56 million a year ago. Net profit for the period was INR 198.61 million compared to INR 79.11 million a year ago. Diluted and basic earnings per share after extraordinary items were INR 62.14 compared to INR 24.75 a year ago. Diluted and basic earnings per share before extraordinary items were INR 20.87 compared to INR 26.28 a year ago.

Novartis India Ltd. Approves Dividend for the Year Ended March 31, 2016; Announces Resignation of Dinesh Charak as Director and Whole Time Director

Novartis India Ltd. announced that the Board of Directors of the company at its meeting held on May 26, 2016, has considered and approved the dividend recommendation of INR 10 per equity share of INR 5 each for the year ended March 31, 2016. The Board accepted the resignation of Mr. Dinesh Charak as Director and Whole Time Director of the company from the close of business hours with effect from May 26, 2016.

Novartis India Limited to Report Fiscal Year 2016 Results on May 26, 2016

Novartis India Limited announced that they will report fiscal year 2016 results on May 26, 2016

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCBA:IN 724.80 INR -103.05

500672 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 500672.
View Industry Companies
 

Industry Analysis

500672

Industry Average

Valuation 500672 Industry Range
Price/Earnings 34.4x
Price/Sales 2.8x
Price/Book 2.0x
Price/Cash Flow 11.3x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVARTIS INDIA LTD, please visit www.novartis.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.